Neumora Therapeutics, Inc. (NMRA)Healthcare | Biotechnology | Watertown, United States | NasdaqGS
1.39 USD
-0.09
(-6.081%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 1.41 +0.02 (1.432%) ⇧ (Aug. 28, 2026, 7:31 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 1:05 a.m. EDT
Neumora Therapeutics is currently a distressed biotech play defined by catastrophic clinical failure and a collapsing business model. The company recently failed late-stage trials for its lead depression drug, triggering a 49% stock plunge, a 35% workforce reduction, and the scrapping of that entire pipeline segment. Fundamentally, the picture is dire: the stock has lost 86% of its value in the last year, the company is burning through cash with negative free cash flow of nearly $100 million, and it carries significant debt relative to its tiny market cap. While the balance sheet shows a current ratio above 4, suggesting some liquidity runway, the operational reality is that the core product portfolio is being dismantled. Analysts remain bullish on paper with a mean target of $6, but this ignores the fundamental destruction of value and the high probability of further dilution or bankruptcy as the company pivots. The options market confirms this pessimism, with traders loading up on puts at the $2.00 level, betting on further decline. There is no reliable path to recovery without a miraculous new asset discovery, making this a high-risk speculative trap rather than an investment opportunity. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.070632 |
| MSTL | 0.130267 |
| AutoARIMA | 0.138635 |
| AutoETS | 0.138636 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 27% |
| H-stat | 0.04 |
| Ljung-Box p | 0.198 |
| Jarque-Bera p | 7.378546864975363e-205 |
| Excess Kurtosis | 20.82 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 119.616 |
| Market Cap | 261,175,296 |
| Forward P/E | -2.08 |
| Beta | 2.78 |
| Website | https://www.neumoratx.com |
As of Aug. 22, 2026, 1:05 a.m. EDT: Speculators are overwhelmingly positioning for downside protection rather than upside participation. Put volume and open interest vastly exceed call volume across all expirations, with massive concentration in the $2.00 strike for September and October. This indicates a strong consensus among traders that the stock will struggle to recover from recent lows, despite some speculative call buying at distant $5.00 strikes.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.2011494 |
| Address1 | 260 Arsenal Place |
| Address2 | Suite 1 |
| All Time High | 21.0 |
| All Time Low | 0.611 |
| Ask | 10.0 |
| Ask Size | 4 |
| Average Analyst Rating | 1.8 - Buy |
| Average Daily Volume10 Day | 822,090 |
| Average Daily Volume3 Month | 1,894,290 |
| Average Volume | 1,894,290 |
| Average Volume10Days | 822,090 |
| Beta | 2.779 |
| Bid | 1.08 |
| Bid Size | 2 |
| Book Value | 0.238 |
| City | Watertown |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.39 |
| Current Ratio | 4.496 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 1.51 |
| Day Low | 1.38 |
| Debt To Equity | 119.616 |
| Display Name | Neumora Therapeutics |
| Earnings Call Timestamp End | 1,774,872,000 |
| Earnings Call Timestamp Start | 1,774,872,000 |
| Earnings Timestamp | 1,786,710,600 |
| Earnings Timestamp End | 1,793,881,800 |
| Earnings Timestamp Start | 1,793,881,800 |
| Ebitda | -206,187,008 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.958 |
| Enterprise Value | 197,593,312 |
| Eps Current Year | -0.87163 |
| Eps Forward | -0.66933 |
| Eps Trailing Twelve Months | -1.15 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.6059 |
| Fifty Day Average Change | -0.21590006 |
| Fifty Day Average Change Percent | -0.13444178 |
| Fifty Two Week Change Percent | -20.11494 |
| Fifty Two Week High | 3.65 |
| Fifty Two Week High Change | -2.2600002 |
| Fifty Two Week High Change Percent | -0.6191781 |
| Fifty Two Week Low | 0.83 |
| Fifty Two Week Low Change | 0.56 |
| Fifty Two Week Low Change Percent | 0.6746988 |
| Fifty Two Week Range | 0.83 - 3.65 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,694,698,200,000 |
| Float Shares | 116,363,938 |
| Forward Eps | -0.66933 |
| Forward P E | -2.0767035 |
| Free Cashflow | -99,416,872 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 63 |
| Fullday Change | -0.09 |
| Fullday Change Percent | -6.08108 |
| Fullday Price | 1.4099 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.23251 |
| Held Percent Institutions | 0.60113996 |
| Implied Shares Outstanding | 187,895,912 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,023-09-15 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in Phase 1b clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-861 and NMRA-898, a M4 muscarinic receptor positive allosteric modulators (PAMs) for schizophrenia and other neuropsychiatric disorders. In addition, the company's preclinical phase product includes NMRA-GCase, an activator program for the treatment of Parkinson's Disease; NMRA-CK1d, a casein kinase 1 isoform delta (CK1d) inhibitor program for Amyotrophic Lateral Sclerosis; and NMRA-215 a brain-penetrant oral NLRP3 inhibitor for the treatment of obesity. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts. |
| Long Name | Neumora Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 261,175,296 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_1684602478 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -212,744,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 278,085,949 |
| Number Of Analyst Opinions | 7 |
| Open | 1.5 |
| Operating Cashflow | -180,520,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 857 760 0900 |
| Post Market Change | 0.019899964 |
| Post Market Change Percent | 1.4316521 |
| Post Market Price | 1.4099 |
| Post Market Time | 1,787,959,906 |
| Previous Close | 1.48 |
| Price Eps Current Year | -1.5947133 |
| Price Hint | 4 |
| Price To Book | 5.840336 |
| Profit Margins | 0.0 |
| Quick Ratio | 4.206 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.77778 |
| Region | US |
| Regular Market Change | -0.09 |
| Regular Market Change Percent | -6.08108 |
| Regular Market Day High | 1.51 |
| Regular Market Day Low | 1.38 |
| Regular Market Day Range | 1.38 - 1.51 |
| Regular Market Open | 1.5 |
| Regular Market Previous Close | 1.48 |
| Regular Market Price | 1.39 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 694,554 |
| Return On Assets | -0.7385 |
| Return On Equity | -1.87112 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 187,895,912 |
| Shares Percent Shares Out | 0.0425 |
| Shares Short | 7,991,116 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 7,786,397 |
| Short Name | Neumora Therapeutics, Inc. |
| Short Percent Of Float | 0.0727 |
| Short Ratio | 12.24 |
| Source Interval | 15 |
| State | MA |
| Symbol | NMRA |
| Target High Price | 14.0 |
| Target Low Price | 3.0 |
| Target Mean Price | 6.14286 |
| Target Median Price | 5.0 |
| Total Cash | 116,834,000 |
| Total Cash Per Share | 0.622 |
| Total Debt | 53,252,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.15 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.09775 |
| Two Hundred Day Average Change | -0.70774996 |
| Two Hundred Day Average Change Percent | -0.3373853 |
| Type Disp | Equity |
| Volume | 694,554 |
| Website | https://www.neumoratx.com |
| Zip | 2,472 |